scPharmaceuticals IncNASDAQ:SCPH
- LAST PRICE4.8250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 4.8250
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SCPH |
|---|---|---|
| 09:32 ET | 2149 | 4.61 |
| 09:36 ET | 400 | 4.65 |
| 09:39 ET | 800 | 4.65 |
| 09:41 ET | 1600 | 4.66 |
| 09:50 ET | 100 | 4.645 |
| 09:52 ET | 510 | 4.63 |
| 09:54 ET | 1200 | 4.6 |
| 09:56 ET | 600 | 4.5746 |
| 09:57 ET | 100 | 4.6 |
| 09:59 ET | 100 | 4.6 |
| 10:03 ET | 500 | 4.6 |
| 10:12 ET | 400 | 4.6 |
| 10:15 ET | 100 | 4.6 |
| 10:19 ET | 100 | 4.6 |
| 10:24 ET | 100 | 4.605 |
| 10:26 ET | 250 | 4.63 |
| 10:28 ET | 300 | 4.605 |
| 10:32 ET | 7500 | 4.605 |
| 10:37 ET | 700 | 4.6 |
| 10:39 ET | 500 | 4.6 |
| 10:46 ET | 1240 | 4.61 |
| 10:50 ET | 110 | 4.6 |
| 10:51 ET | 300 | 4.62 |
| 10:53 ET | 600 | 4.65 |
| 10:55 ET | 2179 | 4.66 |
| 10:57 ET | 100 | 4.67 |
| 11:00 ET | 2400 | 4.68 |
| 11:04 ET | 100 | 4.7 |
| 11:06 ET | 200 | 4.68 |
| 11:08 ET | 100 | 4.68 |
| 11:09 ET | 596 | 4.68 |
| 11:11 ET | 100 | 4.66 |
| 11:15 ET | 520 | 4.655 |
| 11:18 ET | 7500 | 4.66 |
| 11:20 ET | 100 | 4.66 |
| 11:26 ET | 100 | 4.66 |
| 11:27 ET | 300 | 4.66 |
| 11:31 ET | 1452 | 4.695 |
| 11:33 ET | 5651 | 4.715 |
| 11:38 ET | 1611 | 4.75 |
| 11:40 ET | 140 | 4.7467 |
| 11:45 ET | 100 | 4.8 |
| 11:47 ET | 725 | 4.76 |
| 11:54 ET | 500 | 4.77 |
| 11:56 ET | 3261 | 4.7945 |
| 12:00 ET | 7937 | 4.875 |
| 12:02 ET | 1095 | 4.8999 |
| 12:05 ET | 32592 | 4.8 |
| 12:12 ET | 100 | 4.805 |
| 12:14 ET | 2666 | 4.8 |
| 12:18 ET | 4330 | 4.9 |
| 12:21 ET | 300 | 4.8862 |
| 12:32 ET | 100 | 4.88 |
| 12:36 ET | 664 | 4.88 |
| 12:43 ET | 13270 | 4.865 |
| 12:50 ET | 861 | 4.86 |
| 12:54 ET | 690 | 4.85 |
| 12:56 ET | 2706 | 4.825 |
| 12:57 ET | 400 | 4.805 |
| 01:03 ET | 200 | 4.805 |
| 01:21 ET | 100 | 4.81 |
| 01:24 ET | 400 | 4.81 |
| 01:26 ET | 200 | 4.8 |
| 01:28 ET | 6119 | 4.8 |
| 01:46 ET | 400 | 4.8077 |
| 01:48 ET | 771 | 4.79 |
| 01:50 ET | 700 | 4.79 |
| 01:51 ET | 7500 | 4.8 |
| 01:53 ET | 3700 | 4.8 |
| 01:55 ET | 2100 | 4.8 |
| 01:57 ET | 39537 | 4.8 |
| 02:06 ET | 1200 | 4.83 |
| 02:11 ET | 100 | 4.83 |
| 02:18 ET | 1446 | 4.83 |
| 02:26 ET | 987 | 4.8277 |
| 02:29 ET | 100 | 4.83 |
| 02:31 ET | 400 | 4.83 |
| 02:33 ET | 177 | 4.8291 |
| 02:38 ET | 674 | 4.84 |
| 02:40 ET | 2262 | 4.85 |
| 02:54 ET | 300 | 4.87 |
| 02:56 ET | 2225 | 4.91 |
| 02:58 ET | 2533 | 4.895 |
| 03:00 ET | 1800 | 4.88 |
| 03:02 ET | 100 | 4.865 |
| 03:03 ET | 7368 | 4.8 |
| 03:05 ET | 9163 | 4.805 |
| 03:07 ET | 10039 | 4.795 |
| 03:09 ET | 671 | 4.805 |
| 03:12 ET | 200 | 4.82 |
| 03:14 ET | 1000 | 4.85 |
| 03:20 ET | 100 | 4.835 |
| 03:21 ET | 100 | 4.835 |
| 03:23 ET | 563 | 4.84 |
| 03:27 ET | 12600 | 4.83 |
| 03:30 ET | 6032 | 4.8 |
| 03:34 ET | 400 | 4.8001 |
| 03:36 ET | 200 | 4.82 |
| 03:38 ET | 100 | 4.81 |
| 03:39 ET | 1841 | 4.815 |
| 03:41 ET | 16964 | 4.79 |
| 03:43 ET | 720 | 4.81 |
| 03:45 ET | 700 | 4.81 |
| 03:48 ET | 605 | 4.81 |
| 03:50 ET | 300 | 4.81 |
| 03:52 ET | 1182 | 4.81 |
| 03:54 ET | 2362 | 4.83 |
| 03:56 ET | 931 | 4.83 |
| 03:57 ET | 610 | 4.835 |
| 03:59 ET | 15827 | 4.825 |
May 15, 2024
DJ scPharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co., from 7:07AM ET on Wednesday May 15, 2024 by Dow Jones
7:07AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
*DJ scPharmaceuticals 1Q Loss/Shr 36c >SCPH, from 4:01PM ET on Tuesday May 14, 2024 by Dow Jones
4:01PM ET on Tuesday May 14, 2024 by Dow JonesscPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Tuesday May 14, 2024 by Dow Jones
4:01PM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones
May 7, 2024
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
scPharmaceuticals Inc | 174.0M | -3.2x | --- |
Biostem Technologies Inc | 146.1M | -15.8x | --- |
Telomir Pharmaceuticals Inc | 183.0M | -12.9x | --- |
ASP Isotopes Inc | 216.2M | -8.8x | --- |
China Health Industries Holdings Inc | 121.2M | -80.3x | --- |
Cellectar Biosciences Inc | 119.4M | -1.0x | --- |
Company Information
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Contact Information
- Headquarters
- 25 Burlington Mall Road, Suite 203BURLINGTON, MA, United States 01803
- Phone
- 617-517-0730
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jack Khattar
- President, Chief Executive Officer, Director
- John Tucker
- Chief Financial Officer
- Rachael Nokes
- Independent Director
- William Abraham
- Independent Director
- Mette Agger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $174.0M |
|---|---|
Revenue (TTM) | $17.6M |
Shares Outstanding | 36.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.11 |
EPS | $-1.49 |
Book Value | $1.03 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 9.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -338.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
